Sarepta Therapeutics (SRPT) PT Raised to $190 at Citi
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts SRPT Hot Sheet
Price: $19.14 +3.24%
Rating Summary:
19 Buy, 18 Hold, 6 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 25 | New: 12
Rating Summary:
19 Buy, 18 Hold, 6 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 25 | New: 12
Join SI Premium – FREE
Citi analyst Joel Beatty raised the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $190.00 (from $177.00) while maintaining a Buy rating.
You May Also Be Interested In
- Datadog (DDOG) PT Lowered to $285 at Rosenblatt
- Freshworks Inc (FRSH) PT Raised to $17 at UBS
- Twilio (TWLO) PT Raised to $320 at Tigress Financial Partners
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
